T he optimal use of existing research evidence to guide design decisions is referred to as evidence-based design. Sackett, Rosenberg, Gray, Haynes, and Richardson's (1996) well-known defi nition of evidence-based practice for any discipline is "the conscientious, explicit, and judicious use of current best evidence in making decisions…" (p. 71). Th is defi nition emphasizes the importance of using evidence, and the "judicious use" also implies the importance of respecting other factors in design decision making, such as a client's preferences, the project budget, the culture of an organization, and even the community context of the project's location.
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Evidence-based design is a relatively new science, and we have far more need for evidence than we have available research fi ndings. In fact, there are far more urban myths (accepted truths with no evidence) about the eff ects of specifi c design features on outcomes than there is real research evidence. So who and what should we believe when making the million-and sometimes billion-dollar decisions that can aff ect healthcare delivery for Weighing the Evidence Jaynelle F. Stichler, DNSc, RN, FACHE, EDAC, FAAN Jaynelle F. Stichler, DNSc, RN, FACHE, EDAC, FAAN many years to come? We are obligated to build the evidence depository with credible and replicable fi ndings from formal research done using our current projects, disseminating these fi ndings in journals such as HERD and at national professional conferences, diff using the evidence in design meetings and team discussions, and then adopting the evidence rather than our traditional routines and practices to guide decisions in future projects.
Research implementation or utilization is the heart of evidence-based nursing (van Achterberg, Schoonhoven, & Grol, 2008) . Everett Rogers' theory for the diff usion of innovation (Rogers, 2003) explains the implementation of research evidence or fi ndings and the rate of adoption of new fi ndings. It indicates that the adoption of new evidence is aff ected by (1) how credible the evidence seems; (2) the users of the evidence with all of their biases and perceived barriers to implementation; (3) how widely communicated the fi ndings are; and (4) the social system in which the evidence will be used. Th us, while the research fi ndings may be clearly known, some will be early adopters of the new fi ndings, whereas others may be late adopters who wait to see how others implement the new ideas into their building designs. Most important to early adoption is the availability of credible, reliable, and valid research fi ndings.
Weighing the Evidence
Let's face it: not all evidence is created equal. Some of the evidence regarding the eff ect of specifi c design features on patient outcomes or organizational performance is weightier than other evidence, meaning that we can be fairly sure that the fi ndings can be used to guide decisions in other design projects. What is it that makes some evidence more reliable? How do we analyze or appraise research fi ndings to determine that they are worthy of implementation? Th ese are critical questions, considering that design decisions have costs associated with them. We want to make these decisions based on the best possible evidence available, not on someone's opinion or an urban myth.
Hierarchies or Levels of Evidence
Hierarchies provide a guide to the strength of available evidence regarding the research methodology used to measure the eff ect of design features on specifi c outcomes and the quality of the research in its elimination of inherent biases. Evans (2002) states, "Hierarchies aim to provide a simple way to communicate a complex array of evidence generated by a variety of research meth-ods…and they provide a level of trust that can be placed on the recommendations, or alert the user when caution is required" (p. 79). Medicine and nursing have developed hierarchies that rank the systematic review of multi-site studies at the highest level of reliability and expert opinion, case studies, and descriptive studies at the lowest level. When making decisions to treat or not to treat, we want to use evidence gained from the systematic review of multiple studies conducted at multiple sites with rigorous research to minimize the possibility that the fi ndings occurred by chance. Th is is based on the belief that if the treatment worked for a large number of others in multiple sites, then it is more likely to work for our patients.
A number of hierarchies or levels from healthcare disciplines and specialties within medicine and nursing are used to rank or "grade" the evidence according to the type of research design employed to develop new knowledge. Th is ranking process can be used to determine the eff ectiveness, appropriateness, and feasibility of applying the evidence to practice. In its simplest form, evidence can be evaluated as "excellent, good, fair and poor," but of course this perspective is fraught with potential bias. Th e U.S. Preventive Services Task Force (USPSTF), a task force of the Agency for Healthcare Research and Quality, has removed this subjectivity from the levels of evidence; it refers to them as the strength of recommendations. According to the USPSTF (2003), "good evidence" refers to consistent results from well-designed studies that directly assess prescribed outcomes and use representative populations. "Fair evidence" is described as suffi cient to determine the prescribed outcomes, but the study may be limited by the number, quality, or consistency of the studies, the generalizability to other settings, and the indirect nature of the fi ndings regarding the outcomes. "Poor evidence" is described as "insuffi cient" to directly assess the eff ects on prescribed outcomes because of fl aws in the research design or methodology, limited sample size to power the eff ect, or lack of information regarding the prescribed outcomes.
It is important to remember that this leveling nomenclature does not refer to rendering a value judgment about a study as good, fair, or poor; rather, it refers to the level (or effi cacy) of the evidence to guide practice (design) decisions. When there is little evidence available, we must use it, realizing that there may be a margin of error in the decisions fl owing from its use. Th is lack of evidence challenges us to conduct research of our own on the eff ects of specifi c design features on desired outcomes, and to disseminate our fi ndings in the fi eld.
Similarly, the Centers for Disease Control and Prevention (CDC) has a tier system for ranking evidence that ranges from Tier 1, the best evidence based on comparison groups with random assignment and an adequate sample size for the study design, to Tier 4, theory-based interventions with no outcome measurements, which is regarded as similar to expert opinion or exploratory research (CDC, 2010) .
Th e Oxford Evidence-Based Medicine Levels for Treatment (Shapiro, 2006) are even more detailed in their approach to ranking evidence, with 15 diff erent categories of rankings ranging from Lev-el 1a, systematic reviews of randomized controlled trials (number 1 has fi ve levels ranging from 1a to 1e), to Level 5, which is described as expert opinion without explicit critical appraisal or based on principles. Th e need for such specifi city is critical, because decisions to treat or not to treat patients may lead to morbidity or mortality among patients within certain groups. Th ese are lifeand-death decisions that require precision-driven evidence to guide providers in practice. Although the decisions of designers and healthcare leaders are critically important, they are more likely to cause risk in terms of fi nancial outcomes or operational ineffi ciencies than to cause the death of patients or providers. Th erefore, the appraisal of evidence related to evidence-based design needs to be rigorous, but it may not require the precision of a 15-level hierarchy.
Recently the American Association of Critical Care Nurses (AACN) developed a task force to evaluate 12 diff erent rating systems used in nursing, medicine, and other fi elds, and it proposed a new evidence-leveling system for individual research designs. Th is includes Level A, metaanalysis (analysis of the synthesis of multiple quantitative studies) and meta-synthesis (synthesis of fi ndings for multiple qualitative studies); Level B, well-designed randomized experimental and nonrandomized comparative studies; and Level C, descriptive and correlative studies, qualitative studies, systematic reviews, and integrative reviews. Th e new rating system also ranks nonresearch evidence from peer-reviewed professional standards (such as the American Institute of Architects Guidelines for Health Care Design) as Level D. Case reports and expert opinions are ranked as Level E, and manufacturer or consulting company recommendations are ranked as Level M (Armola et al., 2009 ). Th is system is quite user friendly and assists the reader in determining the level of evidence provided by published research.
Most important when reviewing the similarities and diff erences among various rating systems is the realization that all evidence should be critically appraised for its eff ectiveness in answering research questions (What is the eff ect of x design on y outcome?); appropriateness (Are the fi ndings in the study appropriate for the study design and sample used?); and feasibility (Is it feasible to use the recommendations from this study in our setting, with our population of patients and providers, and with our set of circumstances?). It should be remembered that evidence-based design is based on the availability and quality of the evidence as well as the consensus of those involved in the process. Not all evidence-regardless of its quality-can be implemented, given the fi nancial, spatial, or other constraints that we sometimes face in the realities of our situations.
Using Levels of Evidence To Appraise Healthcare Design Research Studies
As more evidence emerges from research focused on the eff ect of the built environment on organizational, provider, and patient outcomes, we need to develop a unique system of ranking the evidence for its eff ectiveness, appropriateness, and feasibility. Such hierarchies or rating scales need to be developed by a broad consensus of experts and stakeholders in the fi eld. A hierarchy of evidence adapted from the AACN model may serve as a foundation for discussion related to healthcare design evidence until a consensus is reached for a formal hierarchy that can be used for the critical appraisal of research articles. Table  1 provides a hierarchical rating scale that can be used for healthcare design.
Readers are encouraged to use the Levels of Evidence for Healthcare Design in Table 1 to critically appraise the research articles published in HERD. Remember that the purpose of a critical appraisal using an evidence hierarchy is not to develop a value judgment about the quality of the study or its fi ndings, but rather to provide a tool to assist designers and healthcare leaders in determining whether statements about the effect of specifi c design features on outcomes are based on credible, reliable, and valid evidence. Evidence not supported by researched designs is placed lower on the hierarchy, but it should be recognized that this level also can be considered evidence.
As you read each of the research studies in HERD, decide what level of evidence is provided by the study and place the numerical rating you would Systematic reviews of multiple randomized controlled trials (RCTs) or nonrandomized studies; metaanalysis of multiple experimental or quasi-experimental studies; meta-synthesis of multiple qualitative studies leading to an integrative interpretation
Level 2
Well-designed experimental (randomized) and quasi-experimental (nonrandomized) studies with consistent results compared to other, similar studies
Level 3
Descriptive correlational studies, qualitative studies, integrative or systematic reviews of correlational or qualitative studies, or RCT or quasi-experimental studies with inconsistent results compared to other, similar studies
Level 4
Peer-reviewed professional standards or guidelines with studies to support recommendations
Level 5
Opinions of recognized experts, multiple case studies
Level 6
Recommendations from manufacturers or consultants who may have a fi nancial interest or bias
give it at the top of the article. As the science of healthcare design matures, hopefully we will begin to develop more and more Level 1 and 2 studies, ensuring that design decisions are based on the highest possible level of evidence.
